Salmeterol and fluticasone in young children with multiple-trigger wheeze

Area of Science:

• Pediatric Pulmonology
• Asthma Management
• Pharmacotherapy

Background:

• Current asthma guidelines recommend inhaled corticosteroids (ICS) combined with long-acting beta-agonists (LABA) for children whose symptoms are not controlled by ICS alone.
• The use of LABAs in pediatric asthma patients remains a subject of ongoing debate and research.

Purpose of the Study:

• To evaluate the efficacy of a combination inhaler containing salmeterol and fluticasone propionate compared to fluticasone propionate alone or salmeterol alone.
• The study focused on children aged 4-7 years experiencing multiple-trigger wheeze.

Main Methods:

• A randomized trial involving 105 children with multiple-trigger wheeze.
• Participants received either salmeterol-fluticasone, fluticasone propionate, or salmeterol for 8 weeks.
• Primary outcome was exhaled nitric oxide; secondary outcomes included lung function, respiratory symptoms, and rescue medication use.

Main Results:

• Exhaled nitric oxide levels decreased across all treatment groups, with significant reductions observed in the salmeterol-fluticasone and fluticasone groups compared to salmeterol alone.
• No significant differences were noted in respiratory symptoms or the need for rescue medication.
• Salmeterol-fluticasone demonstrated a statistically significant, albeit small, improvement in lung function compared to fluticasone alone.

Conclusions:

• The combination of salmeterol-fluticasone and fluticasone alone yielded comparable clinical effects in managing multiple-trigger wheeze in children.
• While salmeterol-fluticasone showed a marginal benefit in lung function, initiating therapy with fluticasone alone is considered a reasonable approach for steroid-naive children.
• All tested treatments were well-tolerated by the pediatric participants.